Furthermore, pharmacological inhibition by XL102 was mimicked by genetic ablation of CDK7 that displayed increased levels of p21 and activation of p53 in CDK7KO AML cells, suggesting that p53 activity is controlled by CDK7 [38]. The gene discussed is TP53; the disease is acute myeloid leukemia.